Acinic cell carcinoma of the parotid gland: Timeo Danaos et dona ferentes? A multicenter retrospective analysis focusing on survival outcome

Abstract

Objectives To analyze the demographic data, surgical and adjuvant treatment data and the survival outcomes in adult patients affected by acinic cell carcinoma of the parotid gland (AciCC). Methods A retrospective multicenter analysis of patients treated for AciCC of the parotid gland from 2000 to 2021 was performed. Exclusion criteria were pediatric (0–18 years) patients, the absence of follow-up and patients with secondary metastatic disease to the parotid gland. Multivariable logistic regression was used to determine factors associated with survival. Results The study included 81 adult patients with AciCC of the parotid gland. The median age was 46.3 years (SD 15.81, range 19–84 years), with a gender female prevalence (F = 48, M = 33). The mean follow-up was 77.7 months (min 4–max 361, SD 72.46). The 5 years overall survival (OS) was 97.5%. The 5 years disease-free survival (DFS) was 60%. No statistical differences have been found in prognosis for age (< 65 or ≥ 65 years), sex, surgery type (superficial vs profound parotid surgery), radicality (R0 vs R1 + Rclose), neck dissection, early pathologic T and N stages and adjuvant therapy (p > 0.05). Conclusion This study did not find prognostic factor for poorest outcome. In contrast with the existing literature, our results showed how also high-grade tumours cannot be considered predictive of recurrence or aggressive behaviour.

A Retrospective Multicenter Italian Analysis of Epidemiological, Clinical and Histopathological Features in a Sample of Patients with Acinic Cell Carcinoma of the Parotid Gland

“…We have already shown that recurrence or metastasis, as well as age >65 years, are independent prognostic indicators of tumor aggressiveness [9]. In contrast to other authors [10,11], we showed that the HG phenotype could not be predictive of recurrence or more aggressive behavior.…”

Systematic Review of Parotid Gland Sarcomas: Multi-Variate Analysis of Clinicopathologic Findings, Therapeutic Approaches and Oncological Outcomes That Affect Survival Rate

“…Indeed, there are not systematic reviews or meta-analysis on the role of RT in parotid gland sarcomas. For epithelial malignant neoplasms of the parotid gland (mucoepidermoid carcinoma, carcinoma ex pleomorphic adenoma, adenoid cystic carcinoma, salivary duct carcinoma, and acinic cell carcinoma), adjuvant RT is taken into consideration in high histological grade, microscopic or macroscopic residual disease, perineural or lymphovascular invasion, T3-4 stage disease and/or positive lymph nodes [15][16][17]. Typically, malignant mesenchymal tumors are described as not sensitive to RT because neoplastic cells, through several mechanisms, may escape from RT-mediated cell death [18].…”

Role of Tumor-Infiltrating Lymphocytes and the Tumor Microenvironment in the Survival of Malignant Parotid Gland Tumors: A Two-Centre Retrospective Analysis of 107 Patients

“…In the context of parotid tumors, mucoepidermoid carcinoma is the most common, followed by adenoid cystic carcinoma and acinic cell carcinoma [ 2 ]. These tumors present a wide and complex range of biological behaviors and are morphologically heterogeneous, making histopathological diagnosis challenging [ 3 ]. The World Health Organization (WHO) has recently updated the classification of SGCs by introducing molecular data to define new entities [ 4 ]; however, molecular typing in this field is still in progress [ 5 ].…”